Effect of Hyperuricaemia on Chronic Renal Disease

Phase 4

• Conditions: Chronic Renal Disease; Hyperuricemia
• Interventions: Drug: 40mg Febuxostat; Drug: 20mg Febuxostat

• Registration Number: NCT03425708
• Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University

Brief Summary

To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention

Detailed Description

This study aims to explore the best effective dose and adverse reaction of febuxostat in lowering serum uric acid to low level in patients with Chronic Renal Disease at different stages. To elucidate that low levels of serum uric acid can delay the progression of renal damage. Promote the application of anti uric acid drugs in the treatment of chronic renal failure and delay the progress of CKD in patients

Study Timeline

• Study Start: 2017-01-01
• Status Verified: 2018-01
• Study First Submitted: 2018-01-13
• Study First Submitted QC: 2018-02-06
• Last Update Submitted: 2018-02-06
• Study First Posted: 2018-02-07
• Last Update Posted: 2018-02-07
• Primary Completion: 2018-12-31
• Study Completion: 2018-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Non-dialysis CKD patients with serum uric acid greater than 7mg/dl.
• eGFR≥15ml/min/1.73m².
• Low salt, low protein, low purine diet.

Exclusion Criteria

• Take drugs that raise blood uric acid at the same time.
• Patients with gout attacks.
• Patients with pregnant, lactating.
• Autosomal dominant polycystic kidney disease.
• Patients with poor general condition and multiple organ failure.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment group2	40mg Febuxostat	Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
Treatment group1	20mg Febuxostat	Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.

Primary Outcome Measures

Name	Time	Method
serum uric acid	up to 6 months	intravenous blood sampling

Secondary Outcome Measures

Name	Time	Method
serum creatinine	up to 6 months	intravenous blood sampling

Trial Locations

Locations (1)

The Affiliated Hospital of Xuzhou Medical University; 🇨🇳 Xuzhou, Jiangsu, China